Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | CASSIOPEIA: D-VTD in high-risk multiple myeloma

Aurore Perrot • 31 Aug 2020
EBMT 2020
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Thalidomide
CASSIOPEIA

Aurore Perrot, MD, PhD, University Hospital Antwerp, Vandoeuvre-lès-Nancy, France, discusses the CASSIOPEIA study (NCT02541383) evaluating the use of daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTD) in autologous transplant-eligible newly-diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Aurore Perrot

0:48
The role of transplant in myeloma
Aurore Perrot • 9 Sep 2021
2:23
Real-world data: treatment pathways for myeloma patients in France
Aurore Perrot • 9 Sep 2021
0:40
Moving towards a cure for myeloma
Aurore Perrot • 9 Sep 2021
5:24
IFM 209 update: 4-year extended follow-up of transplantation outcomes in myeloma
Aurore Perrot • 7 Dec 2020

Related Videos

3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
0:36
The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Sergio Giralt • 16 Apr 2024
1:48
Tackling underrepresentation of minorities in CAR-T clinical trials
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals